GENE.US Genetic Technologies Ltd

Healthcare Life Sciences Tools & Services USA Stocks
0.7650 USD
Close of Sep 13, 2026
1,766 2,120
Market cap
USD 3.71M
P/E
-
P/B
3.29x
ROE
-656.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2024.

Is GENE.US undervalued?

Graham number

The Graham number of Genetic Technologies Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Genetic Technologies Ltd fundamental analysis

No fundamental analysis for Genetic Technologies Ltd yet.

Genetic Technologies Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Genetic Technologies Ltd

Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. The company a…

Full company profile